World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
76
Citations
32355
World Ranking
18628
National Ranking
9280

Overview

Steven M. Rowe is affiliated with the University of Alabama at Birmingham in the United States. Their research primarily falls within the field of Medicine, with a particular focus on Pulmonary and Respiratory Medicine.

The scientist has contributed extensively to the study of cystic fibrosis and related respiratory disorders. Their work encompasses several subfields, including Molecular Biology, Physiology, Epidemiology, and Emergency Medical Services.

The recent papers associated with Steven M. Rowe cover topics in respiratory medicine and cystic fibrosis, including:

  • Human distal airways contain a multipotent secretory cell that can regenerate alveoli (2022, Nature)
  • A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele (2021, American Journal of Respiratory and Critical Care Medicine)
  • Triple Therapy for Cystic Fibrosis Phe508del -Gating and -Residual Function Genotypes (2021, New England Journal of Medicine)
  • Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist (2023, Journal of Clinical Investigation)
  • Disease modification and biomarker development in Parkinson disease (2020, Neurology)

Steven M. Rowe frequently collaborates with other researchers in the field. Notable frequent co-authors include:

  • George M. Solomon
  • David P. Nichols
  • Scott H. Donaldson
  • Guillermo J. Tearney
  • Shah S. Hussain

Their publications appear regularly in several scientific journals, predominantly:

  • Journal of Cystic Fibrosis
  • American Journal of Respiratory and Critical Care Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • UNC Libraries
  • American Journal of Physiology-Lung Cellular and Molecular Physiology

Research topics extensively covered by Steven M. Rowe include:

  • Cystic Fibrosis Research Advances
  • Neonatal Respiratory Health Research
  • Tracheal and airway disorders
  • Asthma and respiratory diseases
  • Pediatric health and respiratory diseases
  • Respiratory viral infections research
  • Dysphagia Assessment and Management

Best Publications

  • A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

    Bonnie W. Ramsey;Jane Davies;N. Gerard McElvaney;Elizabeth Tullis

  • Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

    Jennifer L Taylor-Cousar;Anne Munck;Edward F McKone;Cornelis K van der Ent

  • Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

    Peter G. Middleton;Marcus A. Mall;Pavel Dřevínek;Larry C. Lands

  • Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double-blind, randomised, phase 3 trial

    Harry G M Heijerman;Edward F McKone;Damian G Downey;Eva Van Braeckel

  • A revised airway epithelial hierarchy includes CFTR-expressing ionocytes

    Daniel T. Montoro;Adam L. Haber;Moshe Biton;Moshe Biton;Vladimir Vinarsky

  • Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

    Frank J. Accurso;Steven M. Rowe;J. P. Clancy;Michael P. Boyle

  • Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

    J. P. Clancy;Steven M. Rowe;Frank J. Accurso;Moira L. Aitken

  • VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

    Dominic Keating;Gautham Marigowda;Lucy Burr;Cori Daines

  • The future of cystic fibrosis care: a global perspective

    Scott C Bell;Marcus A Mall;Hector Gutierrez;Milan Macek

  • Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis

    Steven M. Rowe;Sonya L. Heltshe;Sonya L. Heltshe;Tanja Gonska;Scott H. Donaldson

  • Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

    Steven M. Rowe;Cori Daines;Felix C. Ringshausen;Eitan Kerem

  • A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation.

    Amit Gaggar;Patricia L. Jackson;Brett D. Noerager;Philip J. O’Reilly

  • A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

    Michael P Boyle;Scott C Bell;Michael W Konstan;Susanna A McColley

  • Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

    Eitan Kerem;Michael W Konstan;Kris De Boeck;Frank J Accurso

  • VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

    Jane C. Davies;Samuel M. Moskowitz;Cynthia Brown;Alexander Horsley

  • A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation

    Robert J. Snelgrove;Robert J. Snelgrove;Patricia L. Jackson;Matthew T. Hardison;Brett D. Noerager

  • A Foodborne Outbreak of Gastroenteritis Associated with Norwalk-like Viruses: First Molecular Traceback to Deli Sandwiches Contaminated during Preparation

    Nicholas A. Daniels;David A. Bergmire-Sweat;Kellogg J. Schwab;Kellogg J. Schwab;Kate A. Hendricks

  • Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.

    Mark T Dransfield;Steven M Rowe;James E Johnson;William C Bailey

  • “CFTR Modulator Theratyping: Current Status, Gaps and Future Directions”

    John Paul Clancy;Calvin U. Cotton;Scott H. Donaldson;George M. Solomon

  • Cystic Fibrosis Transmembrane Regulator Correctors and Potentiators

    Steven M. Rowe;Alan S. Verkman

Frequent Co-Authors

John P. Clancy
John P. Clancy Cystic Fibrosis Foundation
Eric J. Sorscher
Eric J. Sorscher Emory University
Mark T. Dransfield
Mark T. Dransfield University of Alabama at Birmingham
Michael W. Konstan
Michael W. Konstan Case Western Reserve University
Bonnie W. Ramsey
Bonnie W. Ramsey University of Washington
Amit Gaggar
Amit Gaggar University of Alabama at Birmingham
Marcus A. Mall
Marcus A. Mall Charité - University Medicine Berlin
Isabelle Sermet-Gaudelus
Isabelle Sermet-Gaudelus Necker-Enfants Malades Hospital
Felix Ratjen
Felix Ratjen University of Toronto
David M. Bedwell
David M. Bedwell University of Alabama at Birmingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in the healthcare sector but seeking alternative pathways or flexibility, there are several related online degrees and career options available. These programs can provide faster entry into the workforce or advancement for existing professionals.

If you’re considering nursing, online lpn programs offer a streamlined route to become a Licensed Practical Nurse, often with flexible schedules ideal for busy students. For those wishing to specialize, fast track mental health nursing programs allow registered nurses to quickly earn a master’s degree and move into high-demand psychiatric and mental health roles.

Not all careers in healthcare require a medical degree. Administrative roles are growing rapidly, with the best online mha programs supporting advancement into leadership and management positions. Affordability is also important—explore masters in healthcare administration cost comparisons to find programs suited to your budget and career goals.

These options provide diverse pathways for those passionate about healthcare, whether through direct patient care or administrative leadership.

Best Scientists Citing Steven M. Rowe

Trending Scientists